Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Managed Care

acromegaly

More Like This

First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

Debiopharm Pushes the Boundaries of Innovation in Antibiotic Development Against Gonorrhea with First-In-Human Debio 1453 Trial

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Debiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago